<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>24(9)</volume><submitter>Kelaidonis K</submitter><pubmed_abstract>This study is an extension of current research into a novel class of synthetic antihypertensive drugs referred to as "bisartans", which are bis-alkylated imidazole derivatives bearing two symmetric anionic biphenyltetrazoles. Research to date indicates that bisartans are superior to commercially available hypertension drugs, since the former undergo stronger docking to angiotensin-converting enzyme 2 (ACE2). ACE2 is the key receptor involved in SARS-CoV-2 entry, thus initiating COVID-19 infection and in regulating levels of vasoactive peptides such as angiotensin II and beneficial heptapeptides A(1-7) and Alamandine in the renin-angiotensin system (RAS). In previous studies using in vivo rabbit-iliac arterial models, we showed that Na&lt;sup>+&lt;/sup> or K&lt;sup>+&lt;/sup> salts of selected Bisartan</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>8454</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10179460</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.</pubmed_title><pmcid>PMC10179460</pmcid><pubmed_authors>Vassilaki N</pubmed_authors><pubmed_authors>Hoffmann W</pubmed_authors><pubmed_authors>Mavromoustakos T</pubmed_authors><pubmed_authors>Wegrzyn K</pubmed_authors><pubmed_authors>Matsoukas JM</pubmed_authors><pubmed_authors>Ligielli I</pubmed_authors><pubmed_authors>Ridgway H</pubmed_authors><pubmed_authors>Letsios S</pubmed_authors><pubmed_authors>Chasapis CT</pubmed_authors><pubmed_authors>Kelaidonis K</pubmed_authors><pubmed_authors>Vidali VP</pubmed_authors><pubmed_authors>Moore GJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.</name><description>This study is an extension of current research into a novel class of synthetic antihypertensive drugs referred to as "bisartans", which are bis-alkylated imidazole derivatives bearing two symmetric anionic biphenyltetrazoles. Research to date indicates that bisartans are superior to commercially available hypertension drugs, since the former undergo stronger docking to angiotensin-converting enzyme 2 (ACE2). ACE2 is the key receptor involved in SARS-CoV-2 entry, thus initiating COVID-19 infection and in regulating levels of vasoactive peptides such as angiotensin II and beneficial heptapeptides A(1-7) and Alamandine in the renin-angiotensin system (RAS). In previous studies using in vivo rabbit-iliac arterial models, we showed that Na&lt;sup>+&lt;/sup> or K&lt;sup>+&lt;/sup> salts of selected Bisartan</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-05T11:57:27.628Z</modification><creation>2024-11-15T19:25:54.655Z</creation></dates><accession>S-EPMC10179460</accession><cross_references><pubmed>37176159</pubmed><doi>10.3390/ijms24098454</doi></cross_references></HashMap>